Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Gynecologic Oncology

• Publication date

  2007-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.YGYNO.2007.08.075PMID 17949799PMCID PMC2276605
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma.

  2006cited by this paper
• Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

  2006cited by this paper
• Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial.

  2006cited by this paper
• Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

  2005cited by this paper
• Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

  2005cited by this paper
• Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.

  2004cited by this paper
• Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

  2003cited by this paper
• Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

  2001cited by this paper
• Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

  2000cited by this paper
• Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper

• Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients

  2024cites this paper
• Nanotheranostics for gynecological cancers: a path forward for Africa

  2024cites this paper
• Co-delivery of carboplatin and doxorubicin using ZIF-8 coated chitosan-poly(N-isopropyl acrylamide) nanoparticles through a dual pH/thermo responsive strategy to breast cancer cells.

  2024cites this paper
• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

  2023cites this paper
• A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis

  2022cites this paper
• Tratamiento médico de los cánceres epiteliales de ovario

  2022cites this paper
• Therapeutic Nanoparticles: Advantages and Toxicity

  2022cites this paper
• Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer

  2022cites this paper
• Traitement médical des cancers épithéliaux de l’ovaire

  2022cites this paper
• Combination of nigericin with cisplatin enhances the inhibitory effect of cisplatin on epithelial ovarian cancer metastasis by inhibiting slug expression via the Wnt/β-catenin signalling pathway

  2021cites this paper
• Complement Activation, Immunogenicity, and Immune Suppression as Potential Side Effects of Liposomes

  2021cites this paper
• Risk of corticosteroid treatment and hospitalization after checkpoint inhibitor and radiation therapy in patients with cancer

  2021cites this paper
• Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study

  2021cites this paper
• PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience

  2021cites this paper
• Azidothymidine (AZT) Inhibits Proliferation of Human Ovarian Cancer Cells by Regulating Cell Cycle Progression

  2020cites this paper
• Nanomedicine and chemotherapeutics drug delivery: challenges and opportunities

  2020cites this paper
• Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings

  2020cites this paper
• Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia: a literature review of pharmaceutical and clinical aspects

  2020cites this paper
• Complement Activation: A Potential Threat on the Safety of Poly(ethylene glycol)-Coated Nanomedicines.

  2020cites this paper
• The prognosis of cancer patients undergoing liposomal doxorubicin-based chemotherapy

  2019cites this paper
• Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.

  2019cites this paper
• Emerging serine-threonine kinase inhibitors for treating ovarian cancer

  2019cites this paper
• Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin

  2019cites this paper
• CMAR_A_217329 9899..9905

  2019cites this paper
• Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.

  2019cites this paper
• A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study)

  2019cites this paper
• Epithelial ovarian, fallopian tube, and primary peritoneal cancer

  2018cites this paper
• Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis

  2017cites this paper
• Treatment of Recurrent Epithelial Ovarian Cancer

  2017cites this paper
• Clinical Trials in Ovarian Cancer

  2017cites this paper
• Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer

  2017cites this paper
• Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer.

  2017cites this paper
• Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

  2017cites this paper
• Identification of licofelone through three-dimensional cell culture drug screening as a repurposed agent able to reverse drug resistant and cancer stem cell-like subpopulations in ovarian cancer

  2017cites this paper
• Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

  2017cites this paper
• Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.

  2017cites this paper
• Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum‐free interval: Myth or reality?

  2017cites this paper
• Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment

  2016cites this paper
• Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?

  2016cites this paper
• Chapter 61 – Ovarian Cancer

  2016cites this paper
• Carboplatin and Liposomal Doxorubicin for Ovarian Cancer

  2016cites this paper
• Carboplatin And Cyclosporin A In The Treatment Of Recurrent Epithelial Ovarian Cancer

  2016cites this paper
• Liposomal doxorubicin: the good, the bad and the not-so-ugly

  2016cites this paper
• New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.

  2016cites this paper
• Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model.

  2016cites this paper
• Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.

  2016cites this paper
• Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer.

  2016cites this paper
• Quimioterapia en cáncer epitelial de ovario; revisión de la bibliografía Chemotherapy in epithelial ovarian cancer; literature review

  2016cites this paper
• Role of TGFβ family members on physiological angiogenesis and ovarian cancer

  2016cites this paper
• Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer

  2016cites this paper
• Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.

  2015influential citation
• A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.

  2015cites this paper
• Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian Cancer

  2015cites this paper
• Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration

  2014cites this paper
• Pegylated liposomal doxorubicin in the management of ovarian cancer

  2014cites this paper
• ADVERSE IMMUNE EFFECTS OF LIPOSOMES: IMMUNOGENICITY AND IMMUNE SUPPRESSION

  2014cites this paper
• Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer

  2014cites this paper
• Treatment options in recurrent ovarian cancer: latest evidence and clinical potential

  2014cites this paper
• Secondary Complete Cytoreduction in Recurrent Ovarian Cancer: Benefit of Optimal Patient Selection Using Scoring System

  2014cites this paper
• Major clinical research advances in gynecologic cancer in 2013

  2014cites this paper
• Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options

  2013cites this paper
• A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

  2013cites this paper
• Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study

  2013cites this paper
• Cancer of the Ovary

  2013cites this paper
• Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer.

  2013cites this paper
• Improving Intracellular Doxorubicin Delivery Through Nanoliposomes Equipped with Selective Tumor Cell Membrane Permeabilizing Short-Chain Sphingolipids

  2013cites this paper
• Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

  2013cites this paper
• Increasing the chances for platinum-sensitive ovarian cancer patients.

  2013cites this paper
• Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).

  2013cites this paper
• [Feasibility, morbidity and survival of surgery combined with HIPEC in the management of recurrent ovarian cancer].

  2013cites this paper
• Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life?

  2013cites this paper
• Enhancing Cisplatin Delivery and Anti-tumor Efficacy Using Hyperthermia

  2013cites this paper
• Faisabilité, morbidité et survie de la chirurgie avec CHIP dans la prise en charge des récidives du cancer de l’ovaire

  2013cites this paper
• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

  2013cites this paper
• Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options

  2013cites this paper
• Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin.

  2012cites this paper
• Nanocarriers as Nanomedicines: Design Concepts and Recent Advances

  2012cites this paper
• Recent advances in systemic treatments for ovarian cancer

  2012cites this paper
• Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study.

  2012cites this paper
• Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

  2012cites this paper
• Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer

  2012cites this paper
• Cancer Therapy : Preclinical Lurbinectedin ( PM 01183 ) , a New DNA Minor Groove Binder , Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer

  2012cites this paper
• Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems

  2012cites this paper
• Doxil®--the first FDA-approved nano-drug: lessons learned.

  2012cites this paper
• Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts

  2012cites this paper
• Lurbinectedin ( PM 01183 ) , a New DNA Minor Groove Binder , Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer

  2012cites this paper
• A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

  2012cites this paper
• Systematic review of comparative effectiveness data for oncology orphan drugs.

  2012cites this paper
• Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance.

  2012cites this paper
• Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.

  2011cites this paper
• Development of PEGylated Liposomes

  2011cites this paper
• Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer.

  2011cites this paper
• Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer

  2011cites this paper
• Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort

  2011cites this paper
• Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.

  2010cites this paper
• New advances in ovarian cancer.

  2010cites this paper
• Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs

  2010cites this paper
• Thermosensitive liposomes for the delivery of cancer therapeutics.

  2010cites this paper
• Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer.

  2010cites this paper
• Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial.

  2010cites this paper